L
Larry E. Dillehay
Researcher at Johns Hopkins University
Publications - 51
Citations - 4798
Larry E. Dillehay is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Radioimmunotherapy & Cell cycle. The author has an hindex of 23, co-authored 51 publications receiving 4592 citations. Previous affiliations of Larry E. Dillehay include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Rajani Ravi,Bijoyesh Mookerjee,Zaver M. Bhujwalla,Carrie Hayes Sutter,Dmitri Artemov,Qinwen Zeng,Larry E. Dillehay,Ashima Madan,Gregg L. Semenza,Atul Bedi +9 more
TL;DR: It is demonstrated that homozygous deletion of the p53 tumor suppressor gene via homologous recombination in a human cancer cell line promotes the neovascularization and growth of tumor xenografts in nude mice.
Journal ArticleDOI
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
Fred Bunz,Paul M. Hwang,Chris Torrance,Chris Torrance,Todd Waldman,Yonggang Zhang,Larry E. Dillehay,Jerry R. Williams,Christoph Lengauer,Kenneth W. Kinzler,Bert Vogelstein +10 more
TL;DR: It was found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug, having significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Journal ArticleDOI
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Cherrie K. Donawho,Yan Luo,Yanping Luo,Thomas D. Penning,Joy Bauch,Jennifer J. Bouska,Velitchka Bontcheva-Diaz,Bryan F. Cox,Theodore L. DeWeese,Larry E. Dillehay,Debra Ferguson,Nayereh S. Ghoreishi-Haack,David R. Grimm,Ran Guan,Edward K. Han,Rhonda R. Holley-Shanks,Boris Hristov,Kenneth B. Idler,Ken Jarvis,Eric F. Johnson,Lawrence Kleinberg,Vered Klinghofer,Loren M. Lasko,Xuesong Liu,Kennan C. Marsh,Thomas McGonigal,Jonathan A. Meulbroek,Amanda M. Olson,Joann P. Palma,Luis E. Rodriguez,Yan Shi,Jason Stavropoulos,Alan C. Tsurutani,Gui Dong Zhu,Saul H. Rosenberg,Vincent L. Giranda,David Frost +36 more
TL;DR: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.
Journal ArticleDOI
Cell-cycle arrest versus cell death in cancer therapy
Todd Waldman,Yonggang Zhang,Larry E. Dillehay,Jian Yu,Kenneth W. Kinzler,Bert Vogelstein,Bert Vogelstein,Jerry R. Williams +7 more
TL;DR: It is demonstrated that checkpoint status affects sensitivity to anticancer treatments in vivo, and these findings have important implications for identifying and testing new therapeutic compounds.
Journal ArticleDOI
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria
Chetan Bettegowda,Long H. Dang,Long H. Dang,Ross A. Abrams,David L. Huso,Larry E. Dillehay,Ian Cheong,Nishant Agrawal,Scott Borzillary,J. Michael McCaffery,E. Latice Watson,Kuo-Shyan Lin,Fred Bunz,Kwamena E. Baidoo,Martin G. Pomper,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
TL;DR: Spores of Clostridium novyi-NT spores added little toxicity to the radiotherapeutic regimens, and the combination resulted in long-term remissions in a significant fraction of animals.